BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 15126373)

  • 1. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
    J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.
    Cisternino S; Rousselle C; Debray M; Scherrmann JM
    Pharm Res; 2004 Aug; 21(8):1382-9. PubMed ID: 15359572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
    Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
    Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
    J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2.
    Cattelotte J; Tournier N; Rizzo-Padoin N; Schinkel AH; Scherrmann JM; Cisternino S
    J Neurochem; 2009 Feb; 108(3):767-75. PubMed ID: 19067785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
    Sun A; Wang J
    Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
    Agarwal S; Elmquist WF
    Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
    Eisenblätter T; Hüwel S; Galla HJ
    Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
    Sane R; Agarwal S; Mittapalli RK; Elmquist WF
    J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity.
    Harati R; Villégier AS; Banks WA; Mabondzo A
    J Neuroinflammation; 2012 Dec; 9():273. PubMed ID: 23253775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.
    Poller B; Drewe J; Krähenbühl S; Huwyler J; Gutmann H
    Cell Mol Neurobiol; 2010 Jan; 30(1):63-70. PubMed ID: 19629677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.
    Agarwal S; Uchida Y; Mittapalli RK; Sane R; Terasaki T; Elmquist WF
    Drug Metab Dispos; 2012 Jun; 40(6):1164-9. PubMed ID: 22401960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
    Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
    Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.